AllAnalyst Report
logoMorningstarJanuary 06, 2021

Johnson & Johnson: Likely Democrat Senate Control Ups Potential for New Drug Policies, but Major Changes Look Unlikely

Symbols
JNJ
Sector(s)
Healthcare
Rating
Current Price
$170.22
Fair Value
Economic Moat
Stewardship

Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.
Quotes from this report
Symbol
NamePriceIndustryCurrencyMarket CapMorningstar RatingEconomic MoatUncertainty RatingFair ValuePrice/Fair Value
JNJ
Johnson & Johnson170.22N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Profile

Damien Conover

Sector Director
Damien Conover, CFA, is director of healthcare equity research for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. He is also director of equity strategy, responsible for helping to shape, package, and surface research based on Morningstar's investment philosophy by working closely with the firm's North American sector strategists and directors.Before joining Morningstar in 2007, Conover was an equity research analyst covering the healthcare sector for Raymond James, Bank of Montreal, and Tucker Anthony.Conover holds bachelor's and master's degrees in finance from the University of Wisconsin and was a member of its Applied Security Analysis Program. He also holds the Chartered Financial Analyst® designation.